However, its active ingredient, semaglutide, is also present in Wegovy, the GLP-1 medication FDA-approved for weight loss, and available as a compounded medication
Discover the latest research insights, innovations and treatment trends
Clinical study protocols had participants take their last dose of semaglutide at least 3 days but no more than 10 days before starting tirzepatide
And at Peak Performance, personalized care makes the difference between losing weight and actually transforming your health
Table of Contents Understanding MASLD and MASH in Clinical Practice Mechanisms Behind GLP1s and Liver Health Clinical Evidence Supporting GLP1 MASLD MASH Treatment Choosing the Right GLP1 Agent Monitoring and Managing Patients on GLP1s Future Directions in Therapy FAQs Understanding MASLD and MASH in Clinical Practice MASLD, previously labeled as nonalcoholic fatty liver disease (NAFLD), is now identified by the presence of liver steatosis in individuals with metabolic dysfunction, excluding significant alcohol consumption
Our weight loss compounds are made to help you reach a better weight